Viral infection of the upper respiratory tract causes the common cold, humanity's most frequent illness.1, 2, 3, 4 Acute viral respiratory infections are often categorized as being caused by influenza, the most serious of the viruses, or all others.5, 6, 7 Noninfluenza upper respiratory infection (URI), or common cold, accounts for more than 25 million doctor visits and 40 million lost days of school and work each year in the United States alone.8 Total annual economic costs are estimated at approximately $40 billion in the United States, thus making noninfluenza URI the seventh most expensive illness.9 Although colds are often considered a nuisance rather than a major public health threat, even rhinovirus, the least pathogenic of the common cold viruses, causes death among older and immunocompromised patients.10, 11, 12 On average, children experience four to six symptomatic colds per year, along with several asymptomatic infections. Day care attendance is a reported risk factor.13, 14 For adults, the average is two to three symptomatic colds per year and perhaps one or two asymptomatic infections.15, 16, 17 Some people are especially prone to colds; others get them infrequently.18 We do not really know why. Despite numerous investigations, both biologic and psychosocial determinants of susceptibility are poorly understood.19, 20, 21, 22, 23, 24, 25, 26, 27
Pathophysiology
As an experienced illness, the common cold is characterized by nasal congestion and drainage, sneezing, sore or scratchy throat, cough, and general malaise.28, 29, 30 Cough may or may not be present and tends to occur later in the disease. The cough sometimes lasts for weeks after other symptoms have resolved. The severity of symptoms varies markedly, from barely noticeable to truly debilitating.31 Although true fever is not typical, feelings of feverishness and chilliness are common.32
As an infectious disease, viral URI is characterized by replication of viruses in oral, nasal, and upper respiratory epithelium,33 as well as by activation of local and systemic immune responses.34, 35, 36 Viral replication within epithelial cells triggers cytokine-mediated local inflammatory reactions and recruitment of white blood cells. Parasympathetic neural pathways activate and coordinate local responses. Blood vessels dilate and capillaries leak, causing edematous tissue swelling in the nasal passages.37 Mucous glands are activated, leading to copious discharge in some people. Inflammatory changes in the respiratory epithelium persist for days or weeks after viral shedding subsides. Nevertheless, viruses are sometimes cultured from occasional hosts weeks after the initial infection. Activation of inflammatory mechanisms leading to bronchial constriction makes viral URI the most frequent cause of asthma exacerbation.38
Rhinovirus is the single most common etiologic agent, but it accounts for less than half of all URIs.39, 40, 41 Other viruses include adenovirus, coronavirus, enterovirus, influenza virus, parainfluenza virus, and respiratory syncytial virus.4 , 42 Metapneumovirus,43 , 44 and then bocavirus,45, 46, 47 were more recently discovered. Others as yet undiscovered may exist, given that even the best research laboratories fail to identify an etiologic agent in up to one fourth of people with obvious colds. A few bacteria, such as Streptococcus and Haemophilus influenzae, may cause illnesses with symptoms similar to those of the common cold.
Respiratory viruses follow seasonal patterns. Influenza and respiratory syncytial virus infection occur only during the winter months. Rhinovirus URIs tend to occur in the fall and spring. Adenovirus appears year round. Parainfluenza miniepidemics are episodic. Outbreaks of atypical agents, such as the pertussis bacteria (Bordetella pertussis), may further complicate the picture.
Integrative Therapy
No effective cure exists for the common cold. Even the best positive trials report only modest symptomatic benefit and little or no duration benefit.
Exercise
Although moderate regular exercise protects against infection, excess activity such as running a marathon increases the risk of infection temporarily.48, 49, 50
Nutrition
Chicken Soup
Hot chicken soup is the epitome of traditional cold remedies and could no doubt be supported by many personal testimonies. Chicken soup as a cold remedy is also somewhat supported by at least two human studies, one reporting inhibited neutrophil chemotaxis51 and the other suggesting increased nasal mucus velocity and decreased nasal airflow resistance.52 No randomized controlled trials (RCTs) using patient-oriented outcomes are available. Use of soup made from free-range chickens and substantial quantities of wholesome organic vegetables can be cautiously supported.
Hot Toddy
I have been impressed by the number of people, including several physicians, who have come up after a lecture to tell me that their favorite cold remedy was some form of hot alcoholic beverage, such as a “hot toddy” or hot buttered rum. Although to my knowledge no trials have tested any of these remedies, testimonies of symptomatic benefit should not be totally disregarded. At a societal level, the inverse relationship between moderate regular consumption of alcoholic beverages and the number and severity of colds is well known.22 Those who consume one or two drinks daily have fewer and less severe colds than both those who drink heavily and those who drink not at all. One study found this relationship to be most pronounced for red wine.53 Personally, I like to add a bit of rum to a cup of hot orange juice as a night-time cold remedy. However, this would be contraindicated in patients with alcohol use disorders, in children, in pregnant women, and in anyone needing to use a motor vehicle or operate hazardous machinery.
Healthful exercise, nutritious diet, positive attitude, and healthy relationships are important.
Botanicals
Plants have long been used for medicinal purposes.54, 55, 56, 57 Those used for upper respiratory tract infections are discussed here.
Andrographis: Andrographis paniculata (also Known as Justicia paniculata)
Andrographis is indigenous to Asia, with traditional use most prominent in India. Of 28 Andrographis species, Andrographis paniculata is most commonly used. According to Ayurvedic tradition, andrographis is attributed many important medicinal properties, including use for constipation, digestion, fever, pain, sore throat, and snake bite, as well as to clean the blood. In the West, andrographis is most commonly used as common cold treatment or preventive.
Various laboratories have reported antimicrobial,58 antihyperglyemic,59 , 60 antiinflammatory,61 immunomodulatory,62 , 63 and psychopharmacologic64 effects attributable to andrographolide, flavonoids,65 and other phytochemical constituents. At least 8 RCTs have been conducted, with more than 1000 subjects, to test various andrographis derivatives in URIs, including pharyngitis.66, 67, 68, 69, 70, 71, 72, 73 Systematic reviews by Coon and Ernst74 and Poolsup et al75 concluded the following:
Collectively, the data suggest that A. paniculata is superior to placebo in alleviating the subjective symptoms of uncomplicated upper respiratory tract infection. There is also preliminary evidence of a preventative effect. A. paniculata may be a safe and efficacious treatment for the relief of symptoms of uncomplicated upper respiratory tract infection; more research is warranted.74
Current evidence suggests that A. paniculata extract alone or in combination with A. senticosus extract may be more effective than placebo and may be an appropriate alternative treatment of uncomplicated acute upper respiratory tract infection.75
The most recent trial was not included in those reviews, but it also reported positive results.76 Based on published evidence, and with no indications of serious safety concerns, for adults seeking relief from URI symptoms to try andrographis-based cold remedies seems reasonable. Evidence is not sufficient to favor one product over another, any specific dosing regimen, or any particular standardization procedure for phytochemical content. For pregnant women and children, it seems prudent to recommend against use because of the paucity of data from these populations and because of the possible risk of harm.
Dosage and Standardization
Most clinical trials used products standardized to 4% andrographolide. One reasonable dose regimen would be a 300-mg tablet, four times daily, for the first few days of a cold.
Precautions
This herb is generally well tolerated. It can, however, cause gastrointestinal distress, urticaria, fatigue, and headache. In high doses, it may cause transient elevation of liver enzymes.
Several trials support the use of Andrographis. This is one to watch.
Astragalus: Astragalus membranaceus; Astragalus mongholicus
Astragalus is an important medicinal plant in traditional Chinese medicine.77 Although dozens, if not hundreds, of reported uses are recognized, astragalus extracts are commonly used for both treatment and prevention of the common cold.78 Even though some antiviral activity has been reported, immunomodulation is the purported mechanism of action. Indeed, several studies have reported immunoactivity from astragalus, from enhanced immunoglobulin production to restoration of lost T-cell activity.79, 80, 81, 82, 83 Astragalus root contains astragaloside, flavonoids, and saponins, which are thought to be involved in various hypothesized mechanisms of action. Unfortunately, because no human URI trials have been conducted, no clear recommendations can be made for or against use for treatment or prevention of common cold.
Dosage
The dose is 4 to 7 g (up to a maximum of 28 g) daily.
Precautions
Astragalus is generally well tolerated. Immune suppression can occur with doses greater than 28 g daily.
Chamomile: Matricaria chamomilla; Matricaria recutita (German chamomile); Chamaemelum nobile (Roman chamomile)
Chamomile has been used widely as botanical remedy for centuries for a variety of purposes, including dysmenorrhea, gingivitis, hemorrhoids, infantile colic, indigestion, insomnia, nausea, and vaginitis, as well as topically for numerous skin conditions.84 In the United States, chamomile is most often used as calmative or sedative and for irritable bowel syndrome. However, chamomile is also used for acute respiratory infection, hence it merits inclusion in this discussion. As a remedy for the common cold, chamomile can be taken as herbal tea (i.e., chamomile tea), or the flowering tops can be boiled and the vapors inhaled. One trial testing inhaled vapors from boiling chamomile reported benefit, but the study was of insufficient quality to make firm conclusions.85
Dosage
Although this practice has no good supporting evidence, a cup or two of chamomile tea as supportive treatment for the common cold is certainly safe, and it may be beneficial.
Precautions
Even though no dose-dependent adverse reactions to chamomile are known, allergic sensitivities, including several cases of anaphylaxis, have been reported.86
Echinacea: Echinacea angustifolia; Echinacea purpurea; Echinacea pallida
All dozen species from the genus Echinacea are indigenous to North America. Native peoples discovered dozens of medicinal uses for this plant and later transferred their knowledge to European settlers.87 In the 1920s, echinacea was introduced into Germany, where it has been popular ever since. Today, in North America, Europe, and elsewhere, echinacea extracts are widely used, especially for prevention and treatment of the common cold.88 A considerable body of research exists regarding these uses, including 20 randomized trials with more than 3000 participants, as well as dozens of in vitro and animal studies.89, 90, 91 Although some consensus exists that echinacea extracts display immunologic activities such as macrophage activation and cytokine expression,92, 93, 94, 95, 96, 97, 98, 99 investigators disagree about which of many echinacea-derived phytochemicals are involved. Various alkylamides, glycoproteins, polysaccharides and caffeic, cichoric, and caftaric acids are all implicated. Differing extracts from all three species and from various plant parts have shown immunoactivity in laboratory models. No head-to-head, dose-finding, or viral load outcome studies have been reported.
Double-blind RCTs testing echinacea extracts for prevention and treatment of the common cold were initially positive, and several European trials reported positive results.100, 101, 102, 103, 104, 105, 106, 107 More recent trials, including several in North America, reported mixed results, with the higher-quality trials finding no benefit.108, 109, 110, 111, 112 I myself have directed two trials. Results of the first were flatly negative,113 but results of the second trended in positive directions.114 A trial using Echinacea angustifolia extracts in an induced cold rhinovirus inoculation study found little or no effect.115 However, when all three rhinovirus inoculation studies are considered together, the results look more favorable.116 In general, systematic reviews tend to be positive.117, 118, 119, 120, 121, 122, 123 One negative review argued that the positive trial results could have reflected inadvertent unblinding with either placebo effect or participant reporting bias that contributed to false-positive results.124 The possibility also exists that studies with negative results went unreported. A comprehensive safety review noted some reported allergic reactions but suggested no dose-dependent adverse effects or major drug interaction concerns.125
Given that echinacea extracts appear safe and that most published trial results remain positive, cautious support of echinacea use for adults, especially those with favorable personal experiences and positive expectations, seems reasonable. My opinion is that echinacea use in children should be discouraged because the only pediatric RCT found no positive effects but did report a slight increase in rash among patients randomized to echinacea.126 Although a modest case control study found no adverse effects in pregnancy,127 I caution against this use because the theoretical risks are substantive.
Dosage and Standardization
Trials with positive results have used differing formulations, with preparations made from leaf and flower of Echinacea purpurea used most widely. However, preliminary evidence suggests that alkylamides from roots of E. purpurea and E. angustifolia may have the best bioavailability and immunoactivity.128, 129, 130 Although no consensus on standardization criteria exists, most experts do agree that echinacea extracts should be used as early as possible in the course of a cold, with multiple doses per day for the first few days of symptoms
Actually, more evidence is available on echinacea and vitamin C than on any single conventional therapy. Unfortunately, for every positive trial result, a negative one has been reported.
.
Elderberry: Sambucus nigra
Preliminary research suggested that elderberry extracts may have antiinflammatory and antiviral antiinfluenza properties.131 , 132 One Norwegian RCT of 60 volunteers suggested a potential symptom reduction benefit in influenza-like illness.133 With only one small limited trial and no good safety data, elderberry extract is probably not ready for widespread use.
Dosage
Elderberry fluid extract, 15 mL (1 tablespoon) four times daily, or elderberry extract lozenges (175 mg four times daily), should be taken within the first 48 hours of symptoms.
Garlic: Allium sativum
Garlic is very widely used as a food and flavoring. Medicinally, garlic has dozens, if not hundreds, of reported uses. The most prominent of these is moderation of cholesterol and other lipids, for which modest beneficial activity has been reasonably established.134, 135, 136 Use for prevention or treatment of the common cold is fairly widespread but less well researched.
Although in vitro studies have reported antibacterial and antiviral effects, only one relevant human trial has been conducted. Josling137 reported a trial in which 146 participants were randomized to daily garlic or placebo capsule for 12 weeks. Dramatic between-group differences were observed, with 65 colds in the placebo group and 24 in the garlic group (P <.001). The average cold duration was 5.0 days among those taking placebo compared with 1.5 days among those taking garlic (P <.05). Although the study was reported as a double-blind trial, proof of blinding was not provided. The active treatment was “an allicin-containing garlic supplement” dosed at “one capsule daily.” No further information on extraction methods, phytochemical composition, or amount of garlic was provided. Nevertheless, tentative support of garlic use may be reasonable because the risk of side effects is low, cardiovascular benefits are likely, and garlic is tasty.
Dosage
Fresh garlic should be used in cooking as much and as often as palatable while keeping in mind positive expectations about cardiovascular and cold prevention benefits.
Ginseng: Panax ginseng, Panax quinquefolium
Asian (Panax ginseng) and American (Panax quinquefolium) ginseng are used for many different purposes. The genus name Panax chosen by Linnaeus, in fact, derives from the same root word as Panacea, the Greek goddess of healing. The most widespread medical theory supporting the use of ginseng derives from traditional Chinese medicine.138 Ginseng is thought to have “adaptogenic” attributes, which bring balance, homeostasis, and healing.139, 140, 141 Evidence for effectiveness of a P. ginseng extract in preventing the common cold comes from an Italian trial of 227 people followed for 12 weeks.142 A series of Canadian studies of a polysaccharide-rich P. quinquefolium extract reported immunomodulatory changes.143, 144 An RCT of 198 older nursing home residents reported reductions in both cold and flu episodes.145 A second preventive trial using the same formulation among 323 subjects reported a statistically significant 13% difference in incidence in cold and flu episodes during 4 months of observation.146 The proprietary formula used in this series of research has been approved for use in Canada. In the United States, for prevention-minded people to use small doses of ginseng extracts regularly during cold and flu season seems reasonable, but because evidence is preliminary and safety has not been established, use of ginseng in pregnancy and in children is not advised.
Dosage
For prevention during times of high risk, take 100 mg daily. For acute infection, consider 100 mg twice daily for 9 days.
Precautions
Ginseng is generally well tolerated. The most common side effect is insomnia. It can also cause tachycardia, palpitations, and hypertension.
Goldenseal: Hydrastis canadensis
Goldenseal is among the top-selling botanicals in the United States. In addition to cold remedies, Hydrastis extracts are found in treatments for allergy and in digestive aids, feminine cleansing products, mouthwash, shampoo, skin lotion, and laxatives.84 Goldenseal accompanies echinacea in many cold therapies. However, currently no RCTs have evaluated goldenseal either alone or in combination with echinacea. The phytochemical constituent berberine is pharmacologically active and in overdose can cause significant toxicity, including cardiac arrhythmia and death.147 Goldenseal is contraindicated in pregnancy and lactation. Berberine-rich extracts are included in many traditional Chinese medications. The demand for goldenseal has led to overharvesting and to the substitution of other plants containing berberine or similar compounds. Given these considerations, I do not recommend goldenseal to prevent or treat the common cold.
Peppermint: Mentha piperita
Peppermint and other members of the mint family are widely used for various medicinal purposes, including coughs and colds, as well as for several gastrointestinal purposes. For treating colds, mint teas and infusions are taken internally; mint oils are applied topically. Peppermint oil is composed primarily of menthol, menthone, and menthyl acetate. Menthol especially has been extracted and included in various topical cold remedies classified as “menthol rubs.” Although neither mint teas nor menthol rubs have been subjected to rigorous RCTs for the common cold, both applications seem reasonable from the perspectives of cost, risk, and potential benefit, at least for adults. More concentrated preparations such as peppermint oil should not be applied to the mucosa of infants or young children because direct inflammatory toxicity can result. Bronchospasm, tongue swelling, and even respiratory arrest have been rarely reported.147 , 148
Umckaloabo: Pelargonium sidoides
Various preparations of the South African umckaloabo plant have been used for centuries, following ethnobotanical tradition.149, 150, 151 Three RCTs in adults (N = 746) and three RCTs in children (N = 819) yielded inconsistent yet generally positive findings.152, 153, 154 Although no dose-dependent adverse effects are known, one published report suggested that allergic reactions may be a relatively frequent problem.155 Scientific interest in Pelargonium is relatively recent, and conclusions to date are tentative, yet this seems a reasonable choice for adults looking for a natural treatment for cough, cold, or bronchitis.
Dosage
EPs 7630 is an 11% aqueous ethanolic extract in which 100 g of finished product corresponds to 8 g of extracted plant material. This was the formulation used in the clinical trials, but it may be difficult to find in the United States. The following dosage was used in clinical trials (although I do not support the use of this product in children):
Children younger than 6 years old: 10 drops three times daily
Children 6 to 12 years old: 20 drops three times daily
Those older than 12 years: 30 drops three times daily
A 1 × homeopathic formulation is produced by Nature's Way (Lehi, Utah) called Umcka ColdCare. The dose is 1 mL of the tincture three to five times a day for those older than 12 years.
Precautions
Umckaloabo appears to be safe.
Nutritional Supplements
Vitamin C: Ascorbic acid
The use of vitamin C for prevention and treatment of the common cold became widespread after twice Nobel laureate Linus Pauling promoted his belief in this therapy in the 1950s and 1960s.156 By the early 1970s, three major trials conducted in Toronto by T.W. Anderson et al157, 154, 159 supported some preventive effectiveness. Over the next few decades, more than 30 trials including more than 12,000 participants were reported.160 Approximately half of these trials reported positive results, far more than would be expected by chance, but not enough to convince the more skeptical scientists. Although no clear consensus exists to explain why some trials found benefit and others did not, tentatively concluding some preventive effectiveness seems reasonable, as noted by a Cochrane Systematic Review: “The consistent and statistically significant small benefits on duration and severity for those using regular vitamin C prophylaxis indicates that vitamin C plays some role in respiratory defense mechanisms.”161
Dosage
The evidence supports modest preventive effectiveness for doses of 200 to 500 mg daily. Benefits of larger doses for prevention—or for treatment of new-onset colds—are supported by some trials and systematic reviews,162 but not by others.163 Given the generally accepted safety of ascorbic acid at doses up to several grams per day over short periods, cautious support of its use seems reasonable, especially among those with positive experiences and expectations. (Very high doses, such as the 10 g per day that Linus Pauling was reportedly taking up to his death at age 93 in 1994, have not been tested in trials and hence cannot be supported.) Regular intake of vitamin C–rich foods and juices can be enthusiastically supported because greater intake of fresh fruits and vegetables has no known risks and has been associated with many health benefits in dozens of large observational studies.
Precautions
Large doses of vitamin C can cause diarrhea, gastrointestinal distress, nausea, and heartburn.
Zinc
In some ways, the story of zinc for colds is similar to that of vitamin C. Reportedly, the physician George Eby noticed the rapid recovery from URI in a child hospitalized and given zinc for unrelated reasons. This observation was followed by an RCT in 1984 that reported positive results (but had several methodologic flaws).164 Since then, at least 10 trials with more than 1000 participants have been conducted using various zinc preparations.165, 166, 167, 168, 169 As with vitamin C, only approximately half the studies had positive results, without clear indications of the reason for this disparity. Because most zinc preparations have a distinctive taste, adequate blinding may be an issue, as more skeptical experts have argued.168 , 170
Some concerns also exist over adverse effects, such as unpleasant taste and nausea. Although zinc is an essential mineral, with many known protective effects when it is ingested in foods in appropriate doses,171 , 172 the use of relatively high doses during acute illness may or may not carry some risks. Advocates recommend frequent dosing (every 2 to 3 hours) for the first 2 or 3 days of a cold, a dosing regimen that some patients will not find convenient. More recently, nasal zinc preparations have been devised, and three out of four RCTs reported benefits.170 , 173, 174, 175 Issues of specific preparation, dosing, and blinding complicate interpretation of study results. Nasal irritation is common, and loss of sense of smell has been reported.176 Large, well-designed trials are needed before the benefits of oral or intranasal zinc for the common cold can be said to be proven. My personal recommendation is to support the use of oral or zinc preparations tentatively among those who have experienced benefit or express positive feelings about the treatment, but not to recommend the use of these preparations in children, in women, or in men who have not yet tried it.177 The U.S. Food and Drug Administration (FDA) has collected more than 100 reports of loss of sense of smell for people using nasal zinc. Zicam has been withdrawn from the market. I recommend that nasal zinc not be used.
Dosage
Zinc gluconate, 9 to 24 mg of elemental zinc, is taken every 2 hours while symptomatic.
Precautions
Zinc can inhibit the absorption of other minerals (copper), and nasal formulations have been associated with loss of smell.
Of a dozen trials of zinc, half the results are positive and half are negative.
Probiotics
Probiotics are live bacteria that are thought to support healthy gastrointestinal function. Several trials demonstrated benefit for antibiotic-associated diarrhea,178 and others suggested benefit for irritable bowel syndrome and a few other conditions.179, 180, 181, 182, 183 Reasonably strong preliminary evidence indicates that probiotics may also prevent or ameliorate URI illness. This evidence comes from several trials testing efficacy for preventing cold and flu illness episodes.184, 185, 186, 187, 188, 189, 190 One RCT was of older persons,187 and two involved children.186 , 189 One of these studies was aimed at preventing diarrhea illness, but instead it provided some evidence of cold and flu prevention.189
Dosage
In children, prevention of URI was found with a milk product containing Lactobacillus rhamnosus and Lactobacillus GG (in one study) and Lactobacillus acidophilus and Bifidobacterium animalis (in another). The dose is 5 to 10 billion colony-forming units (CFUs) twice daily.
Precautions
Probiotics should be avoided in persons who have compromised immunity.
Nasal Irrigation and Humidification
Nasal Saline
What could be more healthful and therapeutic than a mild saltwater rinse of the nasal cavities? Although saline nasal lavage is a long-standing tradition in many cultures, only fairly recently has Western biomedicine begun to integrate this practice. Several trials with positive results were conducted in people with allergic rhinitis and chronic sinus symptoms, including one trial at the University of Wisconsin Department of Family Medicine in Madison, Wisconsin.191
To my knowledge only two RCTs of nasal saline in people with the common cold have been conducted. Adam et al192 randomized 140 people to 1 of 3 groups: hypertonic saline, normal tonic saline, or no treatment (two squirts per nostril, three times per day.) No significant differences among the groups were found in terms of duration or severity of symptoms. Diamond et al193 reported a trial in which 955 participants were randomized to 1 of 3 doses of nasal ipratropium, to the “placebo” saline vehicle, or to no treatment at all. The nasal saline vehicle yielded greater benefit compared with no treatment than did any of the ipratropium doses when compared with each other or with saline.
Dosage
I suggest a mild salt water solution made with warm tap water and just enough salt to make it taste like tears (a half teaspoon of salt in 6 oz of warm water). To instill the solution, the head and neck should be nearly horizontal, with one ear down, and the nose should be positioned over a sink or basin. Using a neti pot (small tea pot) or a bulb syringe, gently pour the saline into the higher nostril. The soothing, cleaning fluids will run through the nasal cavity, coming to the other nostril and to the throat. Spit out any fluids from the mouth, and gently blow the nose with a handkerchief or tissue. Repeat the process with the other ear down. I suggest treatment twice daily for the first few days of a cold (see Chapter 109, Sinus Irrigation).
Hot Moist Air
One widespread traditional cold remedy involves the inhalation of hot moist air, often with a botanical or other additive. As noted earlier, the benefits of inhalation of vapors from chamomile tea were reported in one clinical trial.85 At least two RCTs suggested significant benefit of nasal inhalation of unadulterated hot moist air.194 , 195 However, two subsequent trials found no benefit.196 , 197 Although recommending humidification when the air is dry and perhaps advocating the inhalation of hot moist air for those who find it comforting seem reasonable, water boils at 100 °C, and inhalation of vapors near this temperature may cause significant thermal damage. Be careful.
Dosage
Some patients find it beneficial to add a handful of chamomile flowers or 5 to 10 drops of eucalyptus essential oil to the water. Place the head under a towel, and inhale the steaming vapors for 10 to 15 minutes. Repeat as needed.
Mind-Body Therapy
Placebo, Meaning, and Mind-Body Effects
Since 2000, I have read the reports of hundreds of trials and dozens of systematic reviews of common cold research and have become increasingly convinced of the importance of mind-body effects, otherwise described as placebo or meaning effects.198, 199, 200, 201, 202 Positive thinking, suggestion, expectancy, and belief in the therapeutic value of a given remedy can be powerful healing forces. Although regular exercise, balanced nutrition, and tobacco cessation are clearly associated with fewer and less severe illness episodes, so too are positive mental health attributes such as a favorable psychological profile and healthful social relationships. Psychological predispositions, especially sociability and a positive emotional style, are predictive of both symptomatic and physiologic outcomes. For the integrative clinician, this means that understanding an individual's belief system may be a crucial part of the therapeutic encounter. If a patient already believes in a safe therapy, reinforcing that belief may enhance the therapeutic response. If a patient is wary of a remedy mentioned, do not press the issue. Remember that reassurance, empathy, empowerment, and positive prognosis can all be usefully employed in the clinical encounter.
Belief in a therapy—positive expectation—should usually be supported rather than discounted.
Psychosocial Influences
As in virtually all illness, the common cold involves both psychological and physiologic elements and is influenced by social factors. Stress, both acute and chronic, increases risk. In a series of groundbreaking studies, Cohen et al showed that certain psychosocial variables predicted whether volunteers would become infected when they were exposed to rhinovirus. Childhood socioeconomic status,203 number and quality of social relationships,204 acute and chronic stress,205, 206, 207 and negative emotion208 , 209 measured before rhinovirus inoculation all predicted subsequent infection and viral shedding, as well as severity and duration of cold symptoms. Work by other investigators confirmed these findings.210, 211, 212, 213, 214, 215 Together, these observations suggest that maintenance of psychological and social health (positive attitude, healthy relationships) may be as important as maintenance of physical health (exercise, nutrition, hand washing, smoke avoidance) for preventing colds and moderating symptoms.
Conventional Therapies
Antihistamines
Drugs blocking the effects of histamine have been sold as cold remedies for more than a century, but they have been subjected to less in terms of rigorous RCT research than alternatives such as vitamin C, zinc, and echinacea. Nevertheless, some reasonable evidence indicates modest benefit, in terms of reduction of nasal drainage, for first-generation antihistamines such as diphenhydramine, clemastine fumarate, or chlorpheniramine.216, 217, 218, 219 These effects appear to result more from anticholinergic mechanisms than from antihistamine effects, however, and second-generation “nonsedating” antihistamines do not seem to provide benefit.220 For adults who do not mind the potential sedating or membrane-drying effects, or for patients with an allergic response, a first-generation antihistamine may be a reasonable choice. For children, in whom no positive evidence of benefit in colds exists whatsoever, antihistamines should be reserved for allergic rather than infectious rhinitis.
Decongestants
The oral decongestant pseudoephedrine was tested in several clinical trials and appears to have minor benefit in terms of reduction of nasal congestion and drainage.221, 222, 223, 224 Side effects including anxiety, dizziness, insomnia, and palpitations are fairly common. More worrisome is the potential for elevated blood pressure and cardiac arrhythmia. Phenylpropanolamine, for decades a popular over-the-counter decongestant, was taken off the market after studies suggested increased mortality, especially in older persons.225
The topical intranasal decongestant oxymetazoline was shown to decrease nasal airway resistance, as well as mucus production and drainage.226, 227, 228, 229 Intranasal phenylephrine has been less extensively studied but likely has similar effects. Unfortunately, these proven benefits come at the risk of nasal membrane dryness, discomfort, or nosebleed. These drugs should be used for no more than 4 days because rebound nasal congestion can occur.
Conventional treatments such as antihistamines, decongestants, and cough remedies may help slightly with some symptoms, but they do tend to have side effects.
Cough Suppressants
Dextromethorphan, the active ingredient in cough remedies designated with “DM,” is widely used as an over-the-counter cough suppressant. Codeine and, to a lesser extent, hydrocodone are prescribed for cough. Presumably, these drugs work through similar opioid-mediated mechanisms and as such have side effects including sedation, constipation, and, potentially, respiratory suppression. Although most patients and clinicians agree that these remedies work, considerable debate exists over effect size and mechanism of action, given that little appropriate evidence is available.230, 231, 232 The best systematic review of cough remedies for children and adults concludes: “There is no good evidence for or against the effectiveness of OTC medicines in acute cough.”233 Benzonatate (Tessalon Perles) is licensed as a prescription antitussive, but it appears to have been given this indication without any good evidence.
Analgesics and Antipyretics
There is little doubt that acetaminophen and nonsteroidal antiinflammatory drugs (NSAIDs) such as aspirin, ibuprofen, and naproxen are effective for pain and fever, which may accompany common cold. However, some suggestion also exists that viral shedding may be prolonged.234 , 235 Although the limited use of NSAIDs for pain reduction is eminently reasonable, the widespread use of NSAIDs for general common cold symptoms is not justified. Evidence of benefit is marginal, and many thousands of people die each year from NSAID-attributable gastrointestinal hemorrhage and congestive heart failure.236, 237, 238
Anticholinergics
Ipratropium nasal spray was tested in several high-quality RCTs for amelioration of symptoms of infectious and allergic rhinitis.239 , 240 These trials, including a dose-response trial of 955 patients with community-acquired common cold,193 suggested a definite benefit in terms of reduced nasal congestion and drainage. Common side effects of these drugs include headache, uncomfortable nasal dryness, and nosebleed.
Combination Formulas
The multibillion dollar market in cold remedies is dominated by numerous products containing combination formulas. Loopholes in FDA regulations have allowed pharmaceutical companies to mix various decongestants, antihistamines, analgesics, and antitussives and then market them under a variety of brand names with exaggerated or false claims. Although some evidence of effectiveness from early trials exists for combining a decongestant with an antihistamine,216 few, if any, of the currently marketed products have been tested in large, well-controlled RCTs. Personally, I recommend against using any combination cold formula, with a possible exception for patients who are convinced that a specific formula works for them. Perhaps most importantly, clinicians and parents should be made aware that no cold formula has ever been proved to work in children. For pain, acetaminophen (paracetamol) may be justified, but in my opinion, virtually nothing else is.
Prevention Prescription.
-
▪
Eat a nutritious diet with foods rich in vitamin C (fruits and vegetables) and zinc (meat, nuts, cereals, seafood, and pumpkin seeds).
-
▪
Do not smoke.
-
▪
Maintain regular exercise and movement, and be careful not to overstrain.
-
▪
Maintain supportive social relationships.
-
▪
Reduce exposure to people with colds.
-
▪
Reduce stressors, and foster positive emotions.
-
▪
Wash your hands frequently.
-
▪
Obtain an annual influenza vaccine.
-
▪
Vitamin C (200 to 500 mg daily), Panax ginseng (100 mg daily), and probiotics have some effectiveness for the prevention of colds and flu.
Therapeutic Review.
The therapeutic options for the common cold are summarized here. None of these options are proved beyond reasonable doubt to be safe and effective. Nevertheless, they are all reasonable given the best current evidence of benefit and harm.
Botanicals
-
•
Andrographis: 300 mg four times daily as soon as symptoms appear and continued for 3 to 4 days
-
•Echinacea: No one formulation appears to work better than another. Consider one of the following three to four times daily for the first 3 to 4 days of a cold:
-
•1 to 2 mL of extract in juice or water sublingually
-
•150 to 300 mg powdered extract
-
•1 to 5 mL of tincture (1:5 in ethanol)
-
•
-
•Pelargonium/umckaloabo: EPs 7630 is an 11% aqueous ethanolic extract in which 100 g of finished product corresponds to 8 g of extracted plant material. This was the formulation used in the clinical trials but may be difficult to find in the United States. Dosage used in clinical trials:
-
•Those older than 12 years old: 30 drops three times daily
-
•A 1 × homeopathic formulation is produced by Nature's Way called Umcka ColdCare. The dose is 1 mL of the tincture three to five times a day for those older than 12 years.
-
•
Nutritional Supplements
-
•
Vitamin C: 500 to 1000 mg three times daily for the first 3 to 4 days of symptoms
-
•
Zinc gluconate or acetate: 23-mg tablets every 2 hours while awake
Pharmaceuticals
-
•First-generation (sedating) antihistamines may decrease nasal congestion, but they may cause drowsiness.
-
•Diphenhydramine: 25 to 50 mg every 6 hours
-
•Clemastine: 1 to 2 mg two to three times daily as needed
-
•Chlorpheniramine: 4 mg every 6 hours
-
•
-
•Intranasal decongestants appear to be effective in decreasing nasal congestion and drainage, but quite often they cause nasal dryness, irritation, or nosebleed, and, rarely, insomnia, palpitations, or elevated blood pressure.
-
•Intranasal ipratropium appears to be effective in decreasing nasal congestion and drainage, but it may cause headache, nasal irritation, or nosebleed.
-
•Nasal ipratropium 0.03%: two sprays in each nostril two to three times daily. It is also effective for nasal congestion.
-
•
Biomechanical Therapy
-
•
Hot moist air: Consider adding 5 to 10 drops of eucalyptus oil or chamomile tea to the water, and inhale deeply for 10 to 15 minutes.
Nasal Irrigation
-
•
Consider twice daily nasal irrigation with normal or hypertonic saline with a bulb syringe, nasal spray, or neti pot (see Chapter 109, Sinus Irrigation).
-
•
Astragalus, chamomile, garlic, ginseng, peppermint, and chicken soup are all unproven but probably safe, supportive therapies.
Key web resources
Department of Family Medicine, University of Wisconsin School of Medicine and Public Health. http://www.fammed.wisc.edu/research/past-projects/nasal-irrigation
Instructions on nasal irrigation available in English and Spanish
Integrative Medicine, Department of Family Medicine, University of Wisconsin School of Medicine and Public Health. http://www.fammed.wisc.edu/sites/default/files//webfm-uploads/ documents/outreach/im/ss_andrographis.pdf
Monograph on Andrographis
Integrative Medicine, Department of Family Medicine, University of Wisconsin School of Medicine and Public Health. http://www.fammed.wisc.edu/sites/default/files//webfm-uploads/ documents/outreach/im/ss_pelargonium.pdf
Monograph on Pelargonium
National Center for Complementary and Alternative Medicine, National Institutes of Health: http://nccam.nih.gov/news/newsletter/ 2010_february/coldnflu1.htm
Clinical information on the common cold
References
References are available at expertconsult.com.
References
- 1.Campbell H. Acute respiratory infection: a global challenge. Arch Dis Child. 1995;73:281–283. doi: 10.1136/adc.73.4.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Eccles R., Weber O. Birkhauser; Basel: 2009. Common Cold. [Google Scholar]
- 3.Gwaltney J.M. Rhinovirus colds: epidemiology, clinical characteristics and transmission. Eur J Respir Dis. 1983;128:336–339. [PubMed] [Google Scholar]
- 4.Monto A.S. Epidemiology of viral respiratory infections. Am J Med. 2002;112(suppl):12S. doi: 10.1016/s0002-9343(01)01058-0. [DOI] [PubMed] [Google Scholar]
- 5.Centers for Disease Control and Prevention Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep. 2006;55:1–41. [Google Scholar]
- 6.Thompson W.W., Shay D.K., Weintraub E. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186. doi: 10.1001/jama.289.2.179. [DOI] [PubMed] [Google Scholar]
- 7.Thompson W.W., Shay D.K., Weintraub E. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333–1340. doi: 10.1001/jama.292.11.1333. [DOI] [PubMed] [Google Scholar]
- 8.Bertino J.S. Cost burden of viral respiratory infections: issues for formulary decision makers. Am J Med. 2002;112(suppl):49S. doi: 10.1016/s0002-9343(01)01063-4. [DOI] [PubMed] [Google Scholar]
- 9.Fendrick A.M., Monto A.S., Nightengale B., Sarnes M. The economic burden of non–influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–494. doi: 10.1001/archinte.163.4.487. [DOI] [PubMed] [Google Scholar]
- 10.Hicks L.A., Shepard C.W., Britz P.H. Two outbreaks of severe respiratory disease in nursing homes associated with rhinovirus. J Am Geriatr Soc. 2006;54:284–289. doi: 10.1111/j.1532-5415.2005.00529.x. [DOI] [PubMed] [Google Scholar]
- 11.Jennings L.C., Anderson T.P., Beynon K.A. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax. 2008;63:42–48. doi: 10.1136/thx.2006.075077. [DOI] [PubMed] [Google Scholar]
- 12.Louie J.K., Yagi S., Nelson F.A. Rhinovirus outbreak in a long term care facility for elderly persons associated with unusually high mortality. Clin Infect Dis. 2005;41:262–265. doi: 10.1086/430915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ball T.M., Holberg C.J., Aldous M.B. Influence of attendance at day care on the common cold from birth through 13 years of age. Arch Pediatr Adolesc Med. 2002;156:121–126. doi: 10.1001/archpedi.156.2.121. [DOI] [PubMed] [Google Scholar]
- 14.Hurwitz E.L., Gunn W.J., Pinsky P.F., Schonberger L.B. Risk of respiratory illness associated with day-care attendance: a nationwide study. Pediatrics. 1991;87:62–69. [PubMed] [Google Scholar]
- 15.Monto A.S., Ullman B.M. Acute respiratory illness in an American community. JAMA. 1974;227:164–169. [PubMed] [Google Scholar]
- 16.Fox J.P., Hall C.E., Cooney M.K. The Seattle virus watch. II. Objectives, study population and its observation, data processing and summary of illnesses. Am J Epidemiol. 1972;96:270–285. doi: 10.1093/oxfordjournals.aje.a121458. [DOI] [PubMed] [Google Scholar]
- 17.Gwaltney J.M., Hendley J.O., Simon G., Jordan W.S., Jr Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966;275:1261–1268. doi: 10.1056/NEJM196612082752301. [DOI] [PubMed] [Google Scholar]
- 18.Ball T.M., Holberg C.J., Martinez F.D., Wright A.L. Is there a common cold constitution? Ambul Pediatr. 2002;2:261–267. doi: 10.1367/1539-4409(2002)002<0261:itaccc>2.0.co;2. [DOI] [PubMed] [Google Scholar]
- 19.Gwaltney J.M. Viral respiratory infection therapy: historical perspectives and current trials. Am J Med. 2002;112(suppl):41S. doi: 10.1016/s0002-9343(01)01062-2. [DOI] [PubMed] [Google Scholar]
- 20.De Sutter A.I., Lemiengre M., Campbell H. Antihistamines for the common cold. Cochrane Database Syst Rev. 2009;4 doi: 10.1002/14651858.CD001267.pub2. CD001267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Taverner D., Latte J., Draper M. Nasal decongestants for the common cold. Cochrane Database Syst Rev. 2007;1 doi: 10.1002/14651858.CD001953.pub2. CD001953. [DOI] [PubMed] [Google Scholar]
- 22.Turner R.B. New considerations in the treatment and prevention of rhinovirus infections. Pediatr Ann. 2005;34:53–57. doi: 10.3928/0090-4481-20050101-12. [DOI] [PubMed] [Google Scholar]
- 23.Peters E.M. Exercise, immunology and upper respiratory tract infections. Int J Sports Med. 1997;18(suppl):S69–S77. doi: 10.1055/s-2007-972702. [DOI] [PubMed] [Google Scholar]
- 24.Cohen S., Tyrell D.A., Russell M.A. Smoking, alcohol consumption, and susceptibility to the common cold. Am J Public Health. 1993;83:1277–1283. doi: 10.2105/ajph.83.9.1277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Carter J.M. Hand washing decreases risk of colds and flu. J Natl Med Assoc. 2002;94:A11. [PMC free article] [PubMed] [Google Scholar]
- 26.Aiello A.E., Coulborn R.M., Perez V., Larson E.L. Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. Am J Public Health. 2008;98:1372–1381. doi: 10.2105/AJPH.2007.124610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Nieman D.C., Henson D.A., Austin M.D., Sha W. Upper respiratory tract infection is reduced in physically fit and active adults. Br J Sports Med. 2010 doi: 10.1136/bjsm.2010.077875. Nov [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
- 28.Barrett B., Locken K., Maberry R. The Wisconsin Upper Respiratory Symptom Survey: development of an instrument to measure the common cold. J Fam Pract. 2002;51:265–273. [PubMed] [Google Scholar]
- 29.Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5:718–725. doi: 10.1016/S1473-3099(05)70270-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Gwaltney J.M. Clinical significance and pathogenesis of viral respiratory infections. Am J Med. 2002;112(suppl):18S. doi: 10.1016/s0002-9343(01)01059-2. [DOI] [PubMed] [Google Scholar]
- 31.Linder J.A., Singer D.E. Health-related quality of life of adults with upper respiratory tract infections. J Gen Intern Med. 2003;18:802–807. doi: 10.1046/j.1525-1497.2003.21246.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Barrett B., Brown R.L., Mundt M.P. The Wisconsin Upper Respiratory Symptom Survey is responsive, reliable, and valid. J Clin Epidemiol. 2005;58:609–617. doi: 10.1016/j.jclinepi.2004.11.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Gwaltney J.M. Rhinovirus infection of the normal human airway. Am J Respir Crit Care Med. 1995;152:536–539. doi: 10.1164/ajrccm/152.4_Pt_2.S36. [DOI] [PubMed] [Google Scholar]
- 34.Douglas R.G., Alford R.H., Cate T.R., Couch R.B. The leukocyte response during viral respiratory illness in man. Ann Intern Med. 1966;64:521–530. doi: 10.7326/0003-4819-64-3-521. [DOI] [PubMed] [Google Scholar]
- 35.Garofalo R., Patel J.A., Sim C. Production of cytokines by virus-infected human respiratory epithelial cells. J Allergy Clin Immunol. 1993;91:177. [Google Scholar]
- 36.Gern J.E., Vrtis R., Kelly E.A., Dick E.C., Busse W.W. Rhinovirus produces nonspecific activation of lymphocytes through a monocyte-dependent mechanism. J Immunol. 1996;157:1605–1612. [PubMed] [Google Scholar]
- 37.Baraniuk J.N. Sensory, parasympathetic, and sympathetic neural influences in the nasal mucosa. J Allergy Clin Immunol. 1992;90:1045–1050. doi: 10.1016/0091-6749(92)90121-h. [DOI] [PubMed] [Google Scholar]
- 38.Gern J.E., Busse W.W. The role of viral infections in the natural history of asthma. J Allergy Clin Immunol. 2000;106:201–212. doi: 10.1067/mai.2000.108604. [DOI] [PubMed] [Google Scholar]
- 39.Gwaltney J.M. Rhinoviruses. In: Evans A.S., Kaslow R.A., editors. Viral Infections of Humans: Epidemiology and Control. Plenum Press; New York: 1997. pp. 815–838. [Google Scholar]
- 40.Arruda E., Pitkäranta A., Witek T.J. Frequency and history of rhinovirus infections in adults during autumn. J Clin Microbiol. 1997;35:2864–2868. doi: 10.1128/jcm.35.11.2864-2868.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Pitkaranta A., Hayden F.G. Rhinoviruses: important respiratory pathogens. Ann Med. 1998;30:529–537. doi: 10.3109/07853899709002600. [DOI] [PubMed] [Google Scholar]
- 42.Heikkinen T., Jarvinen A. The common cold. Lancet. 2003;361:51–59. doi: 10.1016/S0140-6736(03)12162-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Williams J.V., Harris P.A., Tollefson S.J. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350:443–450. doi: 10.1056/NEJMoa025472. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Sloots T.P., Mackay I.M., Bialasiewicz S. Human metapneumovirus, Australia, 2001–2004. Emerg Infect Dis. 2006;12:1263–1266. doi: 10.3201/eid1208.051239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Allander T., Tammi M.T., Eriksson M. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–12896. doi: 10.1073/pnas.0504666102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Ma X., Endo R., Ishiguro N. Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol. 2006;44:1132–1134. doi: 10.1128/JCM.44.3.1132-1134.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Sloots T.P., McErlean P., Speicher D.J. Evidence of human coronavirus HKU1 and human bocavirus in Australian children. J Clin Virol. 2006;35:99–102. doi: 10.1016/j.jcv.2005.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Nieman D.C. Exercise, upper respiratory tract infection, and the immune system. Med Sci Sports Exerc. 1994;26:128–139. doi: 10.1249/00005768-199402000-00002. [DOI] [PubMed] [Google Scholar]
- 49.Spence L., Brown W.J., Pyne D.B. Incidence, etiology, and symptomatology of upper respiratory illness in elite athletes. Med Sci Sports Exerc. 2007;39:577–586. doi: 10.1249/mss.0b013e31802e851a. [DOI] [PubMed] [Google Scholar]
- 50.Weidner T.G., Cranston T., Schurr T., Kaminsky L.A. The effect of exercise training on the severity and duration of a viral upper respiratory illness. Med Sci Sports Exerc. 1998;30:1578–1583. doi: 10.1097/00005768-199811000-00004. [DOI] [PubMed] [Google Scholar]
- 51.Rennard B.O., Ertl R.F., Gossman G.L. Chicken soup inhibits neutrophil chemotaxis in vitro. Chest. 2000;118:1150–1157. doi: 10.1378/chest.118.4.1150. [DOI] [PubMed] [Google Scholar]
- 52.Saketkhoo K., Januszkiewicz A., Sackner M.A. Effects of drinking hot water, cold water, and chicken soup on nasal mucus velocity and nasal airflow resistance. Chest. 1978;74:408–410. doi: 10.1378/chest.74.4.408. [DOI] [PubMed] [Google Scholar]
- 53.Takkouche B., Regueira-Mendez C., Garcia-Closas R. Intake of wine, beer, and spirits and the risk of clinical common cold. Am J Epidemiol. 2002;155:853–858. doi: 10.1093/aje/155.9.853. [DOI] [PubMed] [Google Scholar]
- 54.Moerman D.E. The medicinal flora of native North America: an analysis. J Ethnopharmacol. 1991;31:1–42. doi: 10.1016/0378-8741(91)90141-y. [DOI] [PubMed] [Google Scholar]
- 55.Schultes R.E., von Reis S. Dioscorides Press; Portland, OR: 1995. Ethnobotany: Evolution of a Discipline. [Google Scholar]
- 56.Farnsworth N.R. The role of ethnopharmacology in drug development. Ciba Found Symp. 1990;154:2–11. doi: 10.1002/9780470514009.ch2. [DOI] [PubMed] [Google Scholar]
- 57.Barrett B., Kiefer D. Medicinal plants, science, and health care. J Herbs Spices Med Plants. 2001;8:1–36. [Google Scholar]
- 58.Singha P.K., Roy S., Dey S. Antimicrobial activity of Andrographis paniculata. Fitoterapia. 2003;74:692–694. doi: 10.1016/s0367-326x(03)00159-x. [DOI] [PubMed] [Google Scholar]
- 59.Hsu J.H., Liou S.S., Yu B.C. Activation of alpha1A-adrenoceptor by andrographolide to increase glucose uptake in cultured myoblast C2C12 cells. Planta Med. 2004;70:1230–1233. doi: 10.1055/s-2004-835857. [DOI] [PubMed] [Google Scholar]
- 60.Yu B.C., Hung C.R., Chen W.C., Cheng J.T. Antihyperglycemic effect of andrographolide in streptozotocin-induced diabetic rats. Planta Med. 2003;69:1075–1079. doi: 10.1055/s-2003-45185. [DOI] [PubMed] [Google Scholar]
- 61.Xia Y.F., Ye B.Q., Li Y.D. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol. 2004;173:4207–4217. doi: 10.4049/jimmunol.173.6.4207. [DOI] [PubMed] [Google Scholar]
- 62.Burgos R.A., Seguel K., Perez M. Andrographolide inhibits IFN-gamma and IL-2 cytokine production and protects against cell apoptosis. Planta Med. 2005;71:429–434. doi: 10.1055/s-2005-864138. [DOI] [PubMed] [Google Scholar]
- 63.Iruretagoyena M.I., Tobar J.A., Gonzalez P.A. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther. 2005;312:366–372. doi: 10.1124/jpet.104.072512. [DOI] [PubMed] [Google Scholar]
- 64.Mandal S.C., Dhara A.K., Maiti B.C. Studies in psychopharmacological activity of Andrographis paniculata extract. Phytother Res. 2001;15:253–256. doi: 10.1002/ptr.704. [DOI] [PubMed] [Google Scholar]
- 65.Kishore P.H., Reddy M.V., Reddy M.K. Flavonoids from Andrographis lineata. Phytochemistry. 2003;63:457–461. doi: 10.1016/s0031-9422(02)00702-1. [DOI] [PubMed] [Google Scholar]
- 66.Caceres D.D., Hancke J.L., Burgos R.A. Use of visual analogue scale measurements (VAS) to assess the effectiveness of standardized Andrographis paniculata extract SHA-10 in reducing the symptoms of common cold: a randomized double blind-placebo study. Phytomedicine. 1999;6:217–223. doi: 10.1016/S0944-7113(99)80012-9. [DOI] [PubMed] [Google Scholar]
- 67.Gabrielian E.S., Shukarian A.K., Goukasova G.I. A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis. Phytomedicine. 2002;9:589–597. doi: 10.1078/094471102321616391. [DOI] [PubMed] [Google Scholar]
- 68.Hancke J. A double-blind study with a new monodrug Kan Jang: decrease of symptoms and improvement in the recovery from common colds. Phytother Res. 1995;9:559–562. [Google Scholar]
- 69.Melchior J. Controlled clinical study of standardized Andrographis paniculata extract in common cold: a pilot trial. Phytomedicine. 1997;3:315–318. doi: 10.1016/S0944-7113(97)80002-5. [DOI] [PubMed] [Google Scholar]
- 70.Melchior J., Spasov A.A., Ostrovskij O.V. Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection. Phytomedicine. 2000;7:341–350. doi: 10.1016/S0944-7113(00)80053-7. [DOI] [PubMed] [Google Scholar]
- 71.Spasov A.A., Ostrovskij O.V., Chernikov M.V., Wikman G. Comparative controlled study of Andrographis paniculata fixed combination, Kan Jang and an Echinacea preparation as adjuvant, in the treatment of uncomplicated respiratory disease in children. Phytother Res. 2004;18:47–53. doi: 10.1002/ptr.1359. [DOI] [PubMed] [Google Scholar]
- 72.Shakhova E.G., Spasov A.A., Ostrovskii O.V. Effectiveness of using the drug Kan-Yang in children with acute respiratory viral infection (clinico-functional data) Vestn Otorinolaringol. 2003;3:48–50. [in Russian] [PubMed] [Google Scholar]
- 73.Thamlikitkul V. Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults. J Med Assoc Thai. 1991;74:437–442. [PubMed] [Google Scholar]
- 74.Coon J.T., Ernst E. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Planta Med. 2004;70:293–298. doi: 10.1055/s-2004-818938. [DOI] [PubMed] [Google Scholar]
- 75.Poolsup N., Suthisisang C., Prathanturarug S. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. J Clin Pharm Ther. 2004;29:37–45. doi: 10.1046/j.1365-2710.2003.00534.x. [DOI] [PubMed] [Google Scholar]
- 76.Saxena R.C., Singh R., Kumar P. A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection. Phytomedicine. 2010;17:178–185. doi: 10.1016/j.phymed.2009.12.001. [DOI] [PubMed] [Google Scholar]
- 77.Upton R. American Herbal Pharmacopoeia; Santa Cruz, CA: 1999:. Astragalus Root: Analytical, Quality Control, and Therapeutic Monograph. 1–25. [Google Scholar]
- 78.McKenna D., Hughes K., Jones K. Astragalus. Altern Ther Health Med. 2002;8:34–40. [PubMed] [Google Scholar]
- 79.Chu D.T., Wong W.L., Mavligit G.M. Immunotherapy with Chinese medicinal herbs. I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by fractionated Astragalus membranaceus in vitro. J Clin Lab Immunol. 1988;25:119–123. [PubMed] [Google Scholar]
- 80.Chu D.T., Wong W.L., Mavligit G.M. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol. 1988;25:125–129. [PubMed] [Google Scholar]
- 81.Sun Y., Hersh E.M., Talpaz M. Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. Cancer. 1983;52:70–73. doi: 10.1002/1097-0142(19830701)52:1<70::aid-cncr2820520114>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- 82.Tan B.K., Vanitha J. Immunomodulatory and antimicrobial effects of some traditional Chinese medicinal herbs: a review. Curr Med Chem. 2004;11:1423–1430. doi: 10.2174/0929867043365161. [DOI] [PubMed] [Google Scholar]
- 83.Block K.I., Mead M.N. Immune system effects of echinacea, ginseng, and astragalus: a review. Integr Cancer Ther. 2003;2:247–267. doi: 10.1177/1534735403256419. [DOI] [PubMed] [Google Scholar]
- 84.Basch E.M., Ulbricht C.E. Mosby; St. Louis: 2005. Natural Standard Herb and Supplement Handbook: The Bottom Line. [Google Scholar]
- 85.Saller R., Beschomer M., Hellenbrecht D. Dose dependency of symptomatic relief of complaints by chamomile steam inhalation in patients with common cold. Eur J Pharmacol. 1990;183:728–729. [Google Scholar]
- 86.Reider N., Sepp N., Fritsch P. Anaphylaxis to camomile: clinical features and allergen cross-reactivity. Clin Exp Allergy. 2000;30:1436–1443. doi: 10.1046/j.1365-2222.2000.00902.x. [DOI] [PubMed] [Google Scholar]
- 87.Flannery M.A. From Rudbeckia to Echinacea: the emergence of the purple cone flower in modern therapeutics. Pharm Hist. 1999;41:52–59. [PubMed] [Google Scholar]
- 88.Brevoort P. The booming U.S. botanical market: a new overview. HerbalGram. 1998;44:33–46. [Google Scholar]
- 89.Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10:66–86. doi: 10.1078/094471103321648692. [DOI] [PubMed] [Google Scholar]
- 90.American Herbal Pharmacopoeia . American Herbal Pharmacopoeia; Santa Cruz, CA: 2004. Echinacea purpurea Root: Standards of Analysis, Quality Control, and Therapeutics. [Google Scholar]
- 91.American Herbal Pharmacopoeia . American Herbal Pharmacopoeia and Therapeutic Compendium; Scotts Valley, CA: 2010. Echinacea angustifolia Root: Standards of Analysis, Quality Control, and Therapeutics. [Google Scholar]
- 92.Barnes J., Anderson L.A., Gibbons S., Phillipson J.D. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005;57:929–954. doi: 10.1211/0022357056127. [DOI] [PubMed] [Google Scholar]
- 93.Bauer R. Chemistry, analysis and immunological investigations of Echinacea phytopharmaceuticals. In: Wagner H., editor. Immunomodulatory Agents from Plants. Birkhauser; Basel: 1999. pp. 41–88. [Google Scholar]
- 94.Burger R.A., Torres A.R., Warren R.P. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol. 1997;19:371–379. doi: 10.1016/s0192-0561(97)00061-1. [DOI] [PubMed] [Google Scholar]
- 95.Elsasser-Beile U., Willenbacher W., Bartsch H.H. Cytokine production in leukocyte cultures during therapy with Echinacea extract. J Clin Lab Anal. 1996;10:441–445. doi: 10.1002/(SICI)1098-2825(1996)10:6<441::AID-JCLA22>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
- 96.Goel V., Chang C., Slama J.V. Alkylamides of Echinacea purpurea stimulate alveolar macrophage function in normal rats. Int Immunopharmacol. 2002;2:381–387. doi: 10.1016/s1567-5769(01)00163-1. [DOI] [PubMed] [Google Scholar]
- 97.Melchart D., Linde K., Worku F. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Altern Complement Med. 1995;1:145–160. doi: 10.1089/acm.1995.1.145. [DOI] [PubMed] [Google Scholar]
- 98.Mishima S., Saito K., Maruyama H. Antioxidant and immuno-enhancing effects of Echinacea purpurea. Biol Pharm Bull. 2004;27:1004–1009. doi: 10.1248/bpb.27.1004. [DOI] [PubMed] [Google Scholar]
- 99.Rehman J., Dillow J.M., Carter S.M. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunol Lett. 1999;68:391–395. doi: 10.1016/s0165-2478(99)00085-1. [DOI] [PubMed] [Google Scholar]
- 100.Bräunig B., Dorn M., Limburg E., Knick E. Echinaceae purpureae radix: zur Stärkung der Körpereigenen abwehr bei grippalen Infekten [Strengthening of the endogenous resistence to influenzal infections. Translation by Ralph McElroy Co., Austin, TX] Z Phytother. 1992;13:7–13. [Google Scholar]
- 101.Bräunig B., Knick E. Therapeutische Erfahrungen mit Echinaceae pallidae bei grippalen Infekten. Naturheilpraxis. 1993;1:72–75. [Google Scholar]
- 102.Brinkeborn R.M., Shah D.V., Degenring F.H. Echinaforce® and other Echinacea fresh plant preparations in the treatment of the common cold. Phytomedicine. 1999;6:1–6. doi: 10.1016/S0944-7113(99)80027-0. [DOI] [PubMed] [Google Scholar]
- 103.Dorn M. Milerung grippaler Effeckte durch ein pflanzliches Immunstimulans. Natur Ganzheitsmed. 1989;2:314–319. [Google Scholar]
- 104.Henneicke-von Zepelin H.H., Hentschel C., Schnitker J. Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory tract infection): results of a randomized, double blind, placebo controlled, multicentre study. Curr Med Res Opin. 1999;15:214–227. doi: 10.1185/03007999909114094. [DOI] [PubMed] [Google Scholar]
- 105.Hoheisel O., Sandberg M., Bertram S. Echinagard treatment shortens the course of the common cold: a double-blind, placebo-controlled clinical trial. Eur J Clin Res. 1997;9:261–268. [Google Scholar]
- 106.Scaglione F., Lund B. Efficacy in the treatment of the common cold of a preparation containing an Echinacea extract. Int J Immunother. 1995;11:163–166. [Google Scholar]
- 107.Schulten B., Bulitta M., Ballering-Brühl B. Efficacy of Echinacea purpurea in patients with a common cold: a placebo-controlled, randomized, double-blind clinical trial. Arzneimittelforschung. 2001;51:563–568. doi: 10.1055/s-0031-1300080. [DOI] [PubMed] [Google Scholar]
- 108.Cohen H.A., Varsano I., Kahan E. Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. Arch Pediatr Adolesc Med. 2004;158:217–221. doi: 10.1001/archpedi.158.3.217. [DOI] [PubMed] [Google Scholar]
- 109.Goel V., Lovlin R., Barton R. Efficacy of a standardized echinacea preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2004;29:75–83. doi: 10.1111/j.1365-2710.2003.00542.x. [DOI] [PubMed] [Google Scholar]
- 110.O'Neil J., Hughes S., Lourie A., Zweifler J. Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2008;100:384–388. doi: 10.1016/S1081-1206(10)60603-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Taylor J.A., Weber W., Standish L. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA. 2003;290:2824–2830. doi: 10.1001/jama.290.21.2824. [DOI] [PubMed] [Google Scholar]
- 112.Yale S.H., Liu K. Echinacea purpurea therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med. 2004;164:1237–1241. doi: 10.1001/archinte.164.11.1237. [DOI] [PubMed] [Google Scholar]
- 113.Barrett B.P., Brown R.L., Locken K. Treatment of the common cold with unrefined echinacea: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:939–946. doi: 10.7326/0003-4819-137-12-200212170-00006. [DOI] [PubMed] [Google Scholar]
- 114.Barrett B., Brown R., Rakel D. Echinacea for treating the common cold: a randomized controlled trial. Ann Intern Med. 2010;153:769–777. doi: 10.7326/0003-4819-153-12-201012210-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Turner R.B., Bauer R., Woelkart K. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med. 2005;353:341–348. doi: 10.1056/NEJMoa044441. [DOI] [PubMed] [Google Scholar]
- 116.Schoop R., Klein P., Suter A., Johnston S.L. Echinacea in the prevention of induced rhinovirus colds. Clin Ther. 2006;28:1–10. doi: 10.1016/j.clinthera.2006.02.001. [DOI] [PubMed] [Google Scholar]
- 117.Barrett B. Medicinal properties of echinacea: a critical review. Phytomedicine. 2003;10:66–86. doi: 10.1078/094471103321648692. [DOI] [PubMed] [Google Scholar]
- 118.Barrett B. Echinacea: a safety review. HerbalGram. 2003;57:36–39. [Google Scholar]
- 119.Linde K., Barrett B., Wolkart K. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;1 doi: 10.1002/14651858.CD000530.pub2. CD000530. [DOI] [PubMed] [Google Scholar]
- 120.Giles J.T., Palat C.T., Chien S.H. Evaluation of Echinacea for treatment of the common cold. Pharmacotherapy. 2000;20:690–697. doi: 10.1592/phco.20.7.690.35173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Islam J., Carter R. Use of Echinacea in upper respiratory tract infection. South Med J. 2005;98:311–318. doi: 10.1097/01.SMJ.0000154783.93532.78. [DOI] [PubMed] [Google Scholar]
- 122.Linde K., Barrett B., Wolkart K.R. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;1 doi: 10.1002/14651858.CD000530.pub2. CD000530. [DOI] [PubMed] [Google Scholar]
- 123.Shah S.A., Sander S., White C.M. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis. 2007;7:473–480. doi: 10.1016/S1473-3099(07)70160-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Caruso T.J., Gwaltney J.M., Jr Treatment of the common cold with echinacea: a structured review. Clin Infect Dis. 2005;40:807–810. doi: 10.1086/428061. [DOI] [PubMed] [Google Scholar]
- 125.Huntley A.L., Thompson C.J., Ernst E. The safety of herbal medicinal products derived from Echinacea species: a systematic review. Drug Saf. 2005;28:387–400. doi: 10.2165/00002018-200528050-00003. [DOI] [PubMed] [Google Scholar]
- 126.Taylor D. Kinship and social structure of the Island Carib. Southwest J Anthropol. 1946;2:180–212. [Google Scholar]
- 127.Gallo M., Sarkar M., Au W. Pregnancy outcome following gestational exposure to Echinacea. Arch Intern Med. 2000;160:3141–3143. doi: 10.1001/archinte.160.20.3141. [DOI] [PubMed] [Google Scholar]
- 128.Agnew L.L., Guffogg S.P., Matthias A. Echinacea intake induces an immune response through altered expression of leucocyte hsp70, increased white cell counts and improved erythrocyte antioxidant defenses. J Clin Pharm Ther. 2005;30:363–369. doi: 10.1111/j.1365-2710.2005.00658.x. [DOI] [PubMed] [Google Scholar]
- 129.Matthias A., Addison R.S., Penman K.G. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion. Life Sci. 2005;77:2018–2029. doi: 10.1016/j.lfs.2005.04.009. [DOI] [PubMed] [Google Scholar]
- 130.Woelkart K., Xu W., Pei Y. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med. 2005;71:701–705. doi: 10.1055/s-2005-871290. [DOI] [PubMed] [Google Scholar]
- 131.Harokopakis E., Albzreh M.H., Haase E.M. Inhibition of proinflammatory activities of major periodontal pathogens by aqueous extracts from elder flower (Sambucus nigra) J Periodontol. 2006;77:271–279. doi: 10.1902/jop.2006.050232. [DOI] [PubMed] [Google Scholar]
- 132.Zakay-Rones Z., Varsano N., Zlotnik M. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama. J Altern Complement Med. 1995;1:361–369. doi: 10.1089/acm.1995.1.361. [DOI] [PubMed] [Google Scholar]
- 133.Zakay-Rones Z., Thom E., Wollan T., Wadstein J. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. J Int Med Res. 2004;32:132–140. doi: 10.1177/147323000403200205. [DOI] [PubMed] [Google Scholar]
- 134.Centre for Reviews and Dissemination Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials (structured abstract) Database of Abstracts of Reviews of Effectiveness. 2005;3 [Google Scholar]
- 135.Agency for Healthcare Research and Quality . Agency for Healthcare Research and Quality; Rockville, MD: 2000. Garlic: Effects on Cardiovascular Risks and Disease, Protective Effects against Cancer, and Clinical Adverse Effects. Publication no. 01-E022. [Google Scholar]
- 136.Stevinson C., Pittler M.H., Ernst E. Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133:420–429. doi: 10.7326/0003-4819-133-6-200009190-00009. [DOI] [PubMed] [Google Scholar]
- 137.Josling P. Preventing the common cold with a garlic supplement: a double-blind, placebo-controlled survey. Adv Ther. 2001;18:189–193. doi: 10.1007/BF02850113. [DOI] [PubMed] [Google Scholar]
- 138.Kaptchuk T.J. Contemporary Books, McGraw-Hill; New York: 2000. The Web That Has No Weaver: Understanding Chinese Medicine. [Google Scholar]
- 139.Kiefer D., Pantuso T. Panax ginseng. Am Fam Physician. 2003;68:1539–1542. [PubMed] [Google Scholar]
- 140.Panossian A., Wikman G., Wagner H. Plant adaptogens. III. Earlier and more recent aspects and concepts on their mode of action. Phytomedicine. 1999;6:287–300. doi: 10.1016/S0944-7113(99)80023-3. [DOI] [PubMed] [Google Scholar]
- 141.Wagner H. Immunostimulants and adaptogens from plants. In: Arnason J.T., Mata R., Romeo J.T., editors. Phytochemistry of Medical Plants. Plenum Press; New York: 1995. pp. 1–18. [Google Scholar]
- 142.Scaglione F., Cattaneo G., Alessandria M., Cogo R. Efficacy and safety of the standardized ginseng extract G 115 for potentiating vaccination against common cold and/or influenza syndrome. Drugs Exp Clin Res. 1996;22:65–72. [PubMed] [Google Scholar]
- 143.McElhaney J.E., Goel V., Toane B. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial. J Altern Complement Med. 2006;12:153–157. doi: 10.1089/acm.2006.12.153. [DOI] [PubMed] [Google Scholar]
- 144.Wang M., Guilbert L.J., Li J. A proprietary extract from North American ginseng (Panax quinquefolium) enhances IL-2 and IFN-gamma productions in murine spleen cells induced by Con-A. Int Immunopharmacol. 2004;4:311–315. doi: 10.1016/j.intimp.2003.12.002. [DOI] [PubMed] [Google Scholar]
- 145.McElhaney J.E., Gravenstein S., Cole S.K. A placebo-controlled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. J Am Geriatr Soc. 2004;52:13–19. doi: 10.1111/j.1532-5415.2004.52004.x. [DOI] [PubMed] [Google Scholar]
- 146.Predy G.N., Goel V., Lovlin R. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial. CMAJ. 2005;173:1043–1048. doi: 10.1503/cmaj.1041470. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 147.Jellin J.M., Gregory P.J., Batz F. Therapeutic Research Faculty; Stockton, CA: 2003. Pharmacist's Letter/Prescriber's Letter: Natural Medicines Comprehensive Database. [Google Scholar]
- 148.Blumenthal M., Hall T., Goldberg A. American Botanical Council; Austin, TX: 2003. The ABC Clinical Guide to Herbs. [Google Scholar]
- 149.Bladt S., Wagner H. From the Zulu medicine to the European phytomedicine Umckaloabo. Phytomedicine. 2007;14(suppl 6):2–4. doi: 10.1016/j.phymed.2006.11.030. [DOI] [PubMed] [Google Scholar]
- 150.Brendler T., van Wyk B.E. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae) J Ethnopharmacol. 2008;119:420–433. doi: 10.1016/j.jep.2008.07.037. [DOI] [PubMed] [Google Scholar]
- 151.Kolodziej H. Aqueous ethanolic extract of the roots of Pelargonium sidoides: new scientific evidence for an old anti-infective phytopharmaceutical. Planta Med. 2008;74:661–666. doi: 10.1055/s-2007-993778. [DOI] [PubMed] [Google Scholar]
- 152.Lizogub V.G., Riley D.S., Heger M. Efficacy of a Pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore (NY) 2007;3:573–584. doi: 10.1016/j.explore.2007.09.004. [DOI] [PubMed] [Google Scholar]
- 153.Matthys H., Heger M. EPs 7630-solution: an effective therapeutic option in acute and exacerbating bronchitis. Phytomedicine. 2007;14(suppl 6):65–68. doi: 10.1016/j.phymed.2006.11.017. [DOI] [PubMed] [Google Scholar]
- 154.Timmer A., Gunther J., Rucker G. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev. 2008;3 doi: 10.1002/14651858.CD006323.pub2. CD006323. [DOI] [PubMed] [Google Scholar]
- 155.de Boer H.J., Hagemann U., Bate J., Meyboom R.H. Allergic reactions to medicines derived from Pelargonium species. Drug Saf. 2007;30:677–680. doi: 10.2165/00002018-200730080-00004. [DOI] [PubMed] [Google Scholar]
- 156.Pauling L. The significance of the evidence about ascorbic acid and the common cold. Proc Natl Acad Sci U S A. 1971;68:2678–2681. doi: 10.1073/pnas.68.11.2678. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 157.Anderson T.W., Reid D.B.W., Beaton G.H. Vitamin C and the common cold: a double-blind Trial. Can Med Assoc J. 1972;107:503–508. [PMC free article] [PubMed] [Google Scholar]
- 158.Anderson T.W., Suranyi G., Beaton G.H. The effect on winter illness of large doses of vitamin C. Can Med Assoc J. 1974;111:31–36. [PMC free article] [PubMed] [Google Scholar]
- 159.Anderson T.W., Beaton G.H., Corey P.N., Spero L. Winter illness and vitamin C: the effect of relatively low doses. Can Med Assoc J. 1975;112:823–826. [PMC free article] [PubMed] [Google Scholar]
- 160.Douglas R.M., Hemila H., D'Souza R. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2004;4 doi: 10.1002/14651858.CD000980.pub2. CD000980. [DOI] [PubMed] [Google Scholar]
- 161.Douglas R.M., Hemila H., D'Souza R. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2007;3 doi: 10.1002/14651858.CD000980.pub3. CD000980. [DOI] [PubMed] [Google Scholar]
- 162.Hemila H. Does Vitamin C alleviate the symptoms of the common cold? A review of current evidence. Scand J Infect Dis. 1994;26:1–6. doi: 10.3109/00365549409008582. [DOI] [PubMed] [Google Scholar]
- 163.Chalmers T.C. Effects of ascorbic acid on the common cold. Am J Med. 1975;58:532–536. doi: 10.1016/0002-9343(75)90127-8. [DOI] [PubMed] [Google Scholar]
- 164.Eby G.A., Davis D.R., Halcomb W.W. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother. 1984;25:20–24. doi: 10.1128/aac.25.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 165.Godfrey J.C., Godfrey N.J., Novick S.G. Zinc for treating the common cold: review of all clinical trials since 1984. Altern Ther Health Med. 1996;2:63–72. [PubMed] [Google Scholar]
- 166.Hulisz D. Efficacy of zinc against common cold viruses: an overview. J Am Pharm Assoc. 2004;44:594–603. doi: 10.1331/1544-3191.44.5.594.Hulisz. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 167.Marshall I. Zinc for the common cold. Cochrane Database Syst Rev. 2006;3 doi: 10.1002/14651858.CD001364. CD001364. [DOI] [PubMed] [Google Scholar]
- 168.Farr B.M., Hayden F.G., Gwaltney J.M. Zinc gluconate lozenges for treating the common cold. Ann Intern Med. 1997;126:738. doi: 10.7326/0003-4819-126-9-199705010-00013. [DOI] [PubMed] [Google Scholar]
- 169.Jackson J.L., Peterson C., Lesho E. A meta-analysis of zinc salt lozenges and the common cold. Arch Intern Med. 1997;157:2373–2376. [PubMed] [Google Scholar]
- 170.Turner R.B. Ineffectiveness of intranasal zinc gluconate for prevention of experimental rhinovirus colds. Clin Infect Dis. 2001;33:1865–1870. doi: 10.1086/324347. [DOI] [PubMed] [Google Scholar]
- 171.Salgueiro M.J., Zubillaga M.B., Lysionek A.E. The role of zinc in the growth and development of children. Nutrition. 2002;18:510–519. doi: 10.1016/s0899-9007(01)00812-7. [DOI] [PubMed] [Google Scholar]
- 172.Walker C.F., Black R.E. Zinc and the risk for infectious disease. Annu Rev Nutr. 2004;24:255–275. doi: 10.1146/annurev.nutr.23.011702.073054. [DOI] [PubMed] [Google Scholar]
- 173.Belongia E.A., Berg R., Liu K.L. A randomized trial of zinc nasal spray for the treatment of upper respiratory illness in adults. Am J Med. 2001;111:103–108. doi: 10.1016/s0002-9343(01)00765-3. [DOI] [PubMed] [Google Scholar]
- 174.Hirt M., Nobel S., Barron E. Zinc nasal gel for the treatment of common cold symptoms: a double-blind, placebo-controlled trial. Ear Nose Throat J. 2000;79:778–782. [PubMed] [Google Scholar]
- 175.Mossad S.B. Effect of zincum gluconicum nasal gel on the duration and symptom severity of the common cold in otherwise healthy adults. QJM. 2003;96:35–43. doi: 10.1093/qjmed/hcg004. [DOI] [PubMed] [Google Scholar]
- 176.Jafek B.W., Linschoten M.R., Murrow B.W. Anosmia after intranasal zinc gluconate use. Am J Rhinol. 2004;18:137–141. [PubMed] [Google Scholar]
- 177.Singh M., Das R.R. Zinc for the common cold. Cochrane Database of Syst Rev. 2011;2 doi: 10.1002/14651858.CD001364.pub3. CD001364. [DOI] [PubMed] [Google Scholar]
- 178.Szajewska H., Ruszczynski M., Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr. 2006;149:367–372. doi: 10.1016/j.jpeds.2006.04.053. [DOI] [PubMed] [Google Scholar]
- 179.Camilleri M. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy. J Clin Gastroenterol. 2008;42(suppl 3):S123–S125. doi: 10.1097/MCG.0b013e3181574393. [DOI] [PubMed] [Google Scholar]
- 180.Ford A.C., Talley N.J., Quigley E.M., Moayyedi P. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum. 2009;52:1805. doi: 10.1007/DCR.0b013e3181ae0ab8. [DOI] [PubMed] [Google Scholar]
- 181.Moayyedi P., Ford A.C., Talley N.J. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59:325–332. doi: 10.1136/gut.2008.167270. [DOI] [PubMed] [Google Scholar]
- 182.Nikfar S., Rahimi R., Rahimi F. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum. 2008;51:1775–1780. doi: 10.1007/s10350-008-9335-z. [DOI] [PubMed] [Google Scholar]
- 183.Sazawal S., Hiremath G., Dhingra U. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomized, placebo-controlled trials. Lancet Infect Dis. 2006;6:374–382. doi: 10.1016/S1473-3099(06)70495-9. [DOI] [PubMed] [Google Scholar]
- 184.Berggren A., Lazou Ahren I., Larsson N., Onning G. Randomized, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defense against viral infections. Eur J Nutr. 2011;50:203–210. doi: 10.1007/s00394-010-0127-6. [DOI] [PubMed] [Google Scholar]
- 185.de Vrese M., Winkler P., Rautenberg P. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine. 2006;24:6670–6674. doi: 10.1016/j.vaccine.2006.05.048. [DOI] [PubMed] [Google Scholar]
- 186.Leyer G.J., Li S., Mubasher M.E. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124:e172–e179. doi: 10.1542/peds.2008-2666. [DOI] [PubMed] [Google Scholar]
- 187.Makino S., Ikegami S., Kume A. Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. Br J Nutr. 2010;104:998–1006. doi: 10.1017/S000711451000173X. [DOI] [PubMed] [Google Scholar]
- 188.Merenstein D., Whittaker C., Chadwell T. Are antibiotics beneficial for patients with sinusitis complaints? A randomized double-blind clinical trial. J Fam Pract. 2005;54:144–151. [PubMed] [Google Scholar]
- 189.Merenstein D.J., Foster J., D'Amico F. A randomized clinical trial measuring the influence of kefir on antibiotic-associated diarrhea: the Measuring the Influence of Kefir (MILK) study. Arch Pediatr Adolesc Med. 2009;163:750–754. doi: 10.1001/archpediatrics.2009.119. [DOI] [PubMed] [Google Scholar]
- 190.Smith T. University of Medicine and Dentistry of New Jersey; Newark, NJ: 2010. Probiotics and Respiratory Tract Infections: An Annotated Bibliography [dissertation] [Google Scholar]
- 191.Rabago D., Zgierska A., Mundt M. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: a randomized controlled trial. J Fam Pract. 2002;51:1049–1055. [PubMed] [Google Scholar]
- 192.Adam P., Stiffman M., Blake R.L. A clinical trial of hypertonic saline nasal spray in subjects with the common cold or rhinosinusitis. Arch Fam Med. 1998;7:39–43. doi: 10.1001/archfami.7.1.39. [DOI] [PubMed] [Google Scholar]
- 193.Diamond L., Dockhorn R.J., Grossman J. A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. J Allergy Clin Immunol. 1995;95:1139–1146. doi: 10.1016/s0091-6749(95)70219-9. [DOI] [PubMed] [Google Scholar]
- 194.Ophir D., Elad Y. Effects of steam inhalation on nasal patency and nasal symptoms in patients with the common cold. Am J Otolaryngol. 1987;3:149–153. doi: 10.1016/s0196-0709(87)80037-6. [DOI] [PubMed] [Google Scholar]
- 195.Tyrell D., Barrow I., Arthur J. Local hyperthermia benefits natural and experimental common colds. BMJ. 1989;298:1280–1283. doi: 10.1136/bmj.298.6683.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 196.Forstall G.J., Macknin M.L., Yen-Lieberman B.R., Medendrop S.V. Effect of inhaling heated vapor on symptoms of the common cold. JAMA. 1994;271:1109–1111. [PubMed] [Google Scholar]
- 197.Macknin M.L., Mathew S., Medendorp S.V. Effect of inhaling heated vapor on symptoms of the common cold. JAMA. 1990;264:989–991. [PubMed] [Google Scholar]
- 198.Moerman D.E., Jonas W.B. Deconstructing the placebo effect and finding the meaning response. Ann Intern Med. 2002;136:471–476. doi: 10.7326/0003-4819-136-6-200203190-00011. [DOI] [PubMed] [Google Scholar]
- 199.Barrett B., Muller D., Rakel D. Placebo, meaning and health. Perspect Biol Med. 2006;49:178–198. doi: 10.1353/pbm.2006.0019. [DOI] [PubMed] [Google Scholar]
- 200.Barrett B., Rakel D., Chewning B. Rationale and methods for a trial assessing placebo, echinacea, and doctor-patient interaction in the common cold. Explore (NY) 2007;3:561–572. doi: 10.1016/j.explore.2007.08.001. [DOI] [PubMed] [Google Scholar]
- 201.Kaptchuk T.J. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med. 2002;136:817–825. doi: 10.7326/0003-4819-136-11-200206040-00011. [DOI] [PubMed] [Google Scholar]
- 202.Rakel D.P., Hoeft T.J., Barrett B.P. Practitioner empathy and the duration of the common cold. Fam Med. 2009;41:494–501. [PMC free article] [PubMed] [Google Scholar]
- 203.Cohen S., Doyle W.J., Turner R.B. Childhood socioeconomic status and host resistance to infectious illness in adulthood. Psychosom Med. 2004;66:553–558. doi: 10.1097/01.psy.0000126200.05189.d3. [DOI] [PubMed] [Google Scholar]
- 204.Cohen S., Doyle W.J., Skoner D.P. Social ties and susceptibility to the common cold. JAMA. 1997;277:1940–1944. [PubMed] [Google Scholar]
- 205.Cohen S., Tyrell D.A.J., Smith A.P. Psychological stress and susceptibility to the common cold. N Engl J Med. 1991;325:606–612. doi: 10.1056/NEJM199108293250903. [DOI] [PubMed] [Google Scholar]
- 206.Cohen S., Tyrrell D.A.J., Smith A.P. Negative life events, perceived stress, negative affect, and susceptibility to the common cold. J Pers Soc Psychol. 1993;64:131–140. doi: 10.1037//0022-3514.64.1.131. [DOI] [PubMed] [Google Scholar]
- 207.Cohen S., Frank E., Doyle W.J. Types of stressors that increase susceptibility to the common cold in healthy adults. Health Psychol. 1998;17:214–223. doi: 10.1037//0278-6133.17.3.214. [DOI] [PubMed] [Google Scholar]
- 208.Cohen S., Doyle W.J., Turner R.B. Emotional style and susceptibility to the common cold. Psychosom Med. 2003;65:652–657. doi: 10.1097/01.psy.0000077508.57784.da. [DOI] [PubMed] [Google Scholar]
- 209.Cohen S., Doyle W.J., Skoner D.P. State and trait negative affect as predictors of objective and subjective symptoms of respiratory viral infections. J Pers Soc Psychol. 1995;68:159–169. doi: 10.1037//0022-3514.68.1.159. [DOI] [PubMed] [Google Scholar]
- 210.Smolderen K.G., Vingerhoets A.J., Croon M.A., Denollet J. Personality, psychological stress, and self-reported influenza symptomatology. BMC Public Health. 2007;7:339. doi: 10.1186/1471-2458-7-339. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 211.Doyle W.J., Gentile D.A., Cohen S. Emotional style, nasal cytokines, and illness expression after experimental rhinovirus exposure. Brain Behav Immun. 2006;20:175–181. doi: 10.1016/j.bbi.2005.05.005. [DOI] [PubMed] [Google Scholar]
- 212.Mohren D.C., Swaen G.M., Borm P.J. Psychological job demands as a risk factor for common cold in a Dutch working population. J Psychosom Res. 2001;50:21–27. doi: 10.1016/s0022-3999(00)00212-9. [DOI] [PubMed] [Google Scholar]
- 213.Stone A.A., Bovbjerg D.H., Neale J.M. Development of common cold symptoms following experimental rhinovirus infection is related to prior stressful life events. Behav Med. 1992;18:115–120. doi: 10.1080/08964289.1992.9936961. [DOI] [PubMed] [Google Scholar]
- 214.Cobb J.M., Steptoe A. Psychosocial stress and susceptibility to upper respiratory tract illness in an adult population sample. Psychosom Med. 1996;58:404–412. doi: 10.1097/00006842-199609000-00003. [DOI] [PubMed] [Google Scholar]
- 215.Takkouche B., Regueira C., Gestal-Otero J.J. A cohort study of stress and the common cold. Epidemiology. 2001;12:345–349. doi: 10.1097/00001648-200105000-00015. [DOI] [PubMed] [Google Scholar]
- 216.Smith M.B., Feldman W. Over-the-counter cold medications: a critical review of clinical trials between 1950 and 1991. JAMA. 1993;269:2258–2263. doi: 10.1001/jama.269.17.2258. [DOI] [PubMed] [Google Scholar]
- 217.De Sutter A.I., Lemiengre M., Campbell H., Mackinnon H.F. Antihistamines for the common cold. Cochrane Database Syst Rev. 2003;3 doi: 10.1002/14651858.CD001267. CD001267. [DOI] [PubMed] [Google Scholar]
- 218.Doyle W.J., McBride T.P., Skoner D.P. A double-blind, placebo-controlled clinical trial of the effect of chlorpheniramine on the response of the nasal airway, middle ear and eustachian tube to provocative rhinovirus challenge. Pediatr Infect Dis J. 1988;7:215–242. doi: 10.1097/00006454-198803000-00033. [DOI] [PubMed] [Google Scholar]
- 219.Gwaltney J.M., Park J., Paul R.A. Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin Infect Dis. 1996;22:656–662. doi: 10.1093/clinids/22.4.656. [DOI] [PubMed] [Google Scholar]
- 220.Muether P.S., Gwaltney J.M., Jr Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold. Clin Infect Dis. 2001;33:1483–1488. doi: 10.1086/322518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 221.Loose I., Winkel M. Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung. 2004;54:513–521. doi: 10.1055/s-0031-1297006. [DOI] [PubMed] [Google Scholar]
- 222.Jawad S.S., Eccles R. Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology. 1998;36:73–76. [PubMed] [Google Scholar]
- 223.Sperber S.J., Sorrentino J.V., Riker D.K., Hayden F.G. Evaluation of an alpha agonist alone and in combination with a nonsteroidal anti-inflammatory agent in the treatment of experimental rhinovirus colds. Bull N Y Acad Med. 2000;65:145–159. [PMC free article] [PubMed] [Google Scholar]
- 224.Taverner D., Danz C., Economos D. The effects of oral pseudoephedrine on nasal patency in the common cold: a double-blind single-dose placebo-controlled trial. Clin Otolaryngol. 1999;24:47–51. doi: 10.1046/j.1365-2273.1999.00208.x. [DOI] [PubMed] [Google Scholar]
- 225.Kernan W.N., Viscoli C.M., Brass L. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2001;343:1826–1832. doi: 10.1056/NEJM200012213432501. [DOI] [PubMed] [Google Scholar]
- 226.Akerlund A., Klint T., Olen L., Rundcrantz H. Nasal decongestant effect of oxymetazoline in the common cold: an objective dose-response study in 106 patients. J Laryngol Otol. 1989;103:743–746. doi: 10.1017/s0022215100109958. [DOI] [PubMed] [Google Scholar]
- 227.Morris S., Eccles R., Martez S.J. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion. Am J Rhinol. 1997;11:109–115. doi: 10.2500/105065897782537197. [DOI] [PubMed] [Google Scholar]
- 228.Taverner D., Latte J., Draper M. Nasal decongestants for the common cold. Cochrane Database Syst Rev. 2004;3 doi: 10.1002/14651858.CD001953.pub2. CD001953. [DOI] [PubMed] [Google Scholar]
- 229.Witek T.J., Jr, Canestrari D.A., Hernandez J.R. Superficial nasal mucosal blood flow and nasal patency following topical oxymetazoline hydrochloride. Ann Allergy. 1992;68:165–168. [PubMed] [Google Scholar]
- 230.Bridges-Webb C. Lack of evidence exists for effectiveness of over-the-counter cough preparations for children with URTI. ACP J Club. 2002;137:106. [PubMed] [Google Scholar]
- 231.Eccles R., Morris S., Jawad M. Lack of effect of codeine in the treatment of cough associated with acute upper respiratory tract infection. J Clin Pharm Ther. 1992;17:175–180. doi: 10.1111/j.1365-2710.1992.tb01289.x. [DOI] [PubMed] [Google Scholar]
- 232.Freestone C., Eccles R. Assessment of the antitussive efficacy of codeine in cough associated with common cold. J Pharm Pharmacol. 1997;49:1045–1049. doi: 10.1111/j.2042-7158.1997.tb06039.x. [DOI] [PubMed] [Google Scholar]
- 233.Schroeder K., Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2004;4 doi: 10.1002/14651858.CD001831.pub2. CD001831. [DOI] [PubMed] [Google Scholar]
- 234.Graham N.M., Burrell C.J., Douglas R.M., Debelle P.D. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis. 1990;162:1277–1282. doi: 10.1093/infdis/162.6.1277. [DOI] [PubMed] [Google Scholar]
- 235.Stanley E.D., Jackson G.G., Panusarn C. Increased virus shedding with aspirin treatment of rhinovirus infection. JAMA. 1975;231:1248–1251. [PubMed] [Google Scholar]
- 236.Fries J.F. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl. 1991;28:6–10. [PubMed] [Google Scholar]
- 237.Andrade S.E., Martinez C., Walker A.M. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol. 1998;51:1357–1365. doi: 10.1016/s0895-4356(98)00076-6. [DOI] [PubMed] [Google Scholar]
- 238.Page J., Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160:777–784. doi: 10.1001/archinte.160.6.777. [DOI] [PubMed] [Google Scholar]
- 239.Borum P., Olsen L., Winther B., Mygind N. Ipratropium nasal spray: a new treatment for rhinorrhea in the common cold. Am Rev Respir Dis. 1981;123:418–420. doi: 10.1164/arrd.1981.123.4.418. [DOI] [PubMed] [Google Scholar]
- 240.Hayden F.G., Diamond L., Wood P.B. Effectiveness and safety of intranasal ipratropium bromide in common colds. Ann Intern Med. 1996;125:89–97. doi: 10.7326/0003-4819-125-2-199607150-00002. [DOI] [PubMed] [Google Scholar]
